PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Zhejiang Hisun Pharmaceutical Co., Ltd.

USPTO PatentsView assignee record — 57 granted patents across 23 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Explore the portfolio See the ranking
57
Total patents granted
23
CPC technology areas
14.9
Avg claims per patent
-61%
5-year filing velocity

The verdict

Zhejiang holds 57 US patents across 23 technology areas — rank #5,994 of 50,000 tracked assignees.

#5,994
of 50,000 US assignees by volume
Top 32%
by Innovation Score (41.9/100)
14.9
avg claims per patent
-61%
filing velocity, last 5 yrs

Portfolio overview

Zhejiang Hisun Pharmaceutical Co., Ltd. has been granted 57 US utility patents between 2015 and 2025, placing Zhejiang Hisun Pharmaceutical Co., Ltd. at rank #5,994 across all assignees tracked by PlainPatent. This portfolio spans 23 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.9 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Zhejiang Hisun Pharmaceutical Co., Ltd. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 41.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 16 grants, compared with 41 in the 2015–2019 window — a -61% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Zhejiang Hisun Pharmaceutical Co., Ltd.'s 14.9 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 23 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Zhejiang Hisun Pharmaceutical Co., Ltd. against peers pursuing similar technology classes.

How does Zhejiang compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Zhejiang holds 57 patents — placing it at rank #5,994 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Zhejiang's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). This entry sits in this band. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

051015 20152016201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Zhejiang Hisun Pharmaceutical Co., Ltd. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 2 3.5%
2016 7 12.3%
2017 11 19.3%
2018 8 14.0%
2019 13 22.8%
2020 5 8.8%
2021 2 3.5%
2022 3 5.3%
2023 2 3.5%
2024 1 1.8%
2025 3 5.3%

Which technologies does Zhejiang Hisun Pharmaceutical Co., Ltd. patent most?

Top 15 of 23 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#5,994

Across all tracked assignees

Innovation Score

41.9 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Zhejiang Hisun Pharmaceutical Co., Ltd. hold?
Zhejiang Hisun Pharmaceutical Co., Ltd. holds 57 US granted patents filed between 2015 and 2025, spanning 23 technology areas.
What is Zhejiang Hisun Pharmaceutical Co., Ltd.'s Innovation Score?
Zhejiang Hisun Pharmaceutical Co., Ltd. has an Innovation Score of 41.9 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Zhejiang Hisun Pharmaceutical Co., Ltd. focus on?
Zhejiang Hisun Pharmaceutical Co., Ltd.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 40 patents. The company has filed patents in 23 CPC subclasses total.
Is Zhejiang Hisun Pharmaceutical Co., Ltd.'s patent filing rate increasing or decreasing?
Zhejiang Hisun Pharmaceutical Co., Ltd.'s recent filing velocity is -61% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Zhejiang Hisun Pharmaceutical Co., Ltd.'s patents?
Zhejiang Hisun Pharmaceutical Co., Ltd.'s patents average 14.9 claims each. This falls within the standard range, providing solid legal coverage.
How is the Zhejiang Hisun Pharmaceutical Co., Ltd. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How Innovation Score Works

Understand the four dimensions behind the composite score
How to Read Patent Data

Plain-English guide to CPC codes, claims, and metrics
Patent Moat Analysis

How companies use patents as competitive barriers

How to use this portfolio

Zhejiang's 57 grants land it in the top 32% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Zhejiang ranks #5,994 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in A61P — see who else leads that technology area. A61P leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

A61P technology

Zhejiang Hisun Pharmaceutical Co., Ltd.'s primary CPC class — all holders and yearly trends
Top 50 patent holders

See where Zhejiang Hisun Pharmaceutical Co., Ltd. ranks among the largest US patent assignees
All technology classes

Browse every CPC technology area by patent activity
How the score works

The four dimensions behind the Innovation Score

Related

All companies → | All technologies → | Rankings →
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology — how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov